Having successfully landed their anti-PD-1 Loqtorzi (toripalimab) in the US, Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. are set to jump-start a partnership bonanza for potential combination therapies using the immuno-oncology drug as the backbone.
Key Takeaways
-
Junshi and Coherus’s anti-PD-1 Loqtorzi (toripalimab) was finally approved in the US on 27 October after one and a half years of twists and turns under review.
Loqtorzi went through twists and turns for its biologics license application with the US Food and Drug Administration over the...